Medrogestone and an LHRH analogue as potential combination therapy for hormone-dependent cancers.
Treatment (5 mg/kg s.c. for 1 to 4 weeks) of adult male rats with medrogestone (Colprone), a compound with progestational and antiandrogenic properties, induced significant atrophy of the ventral prostate without affecting testicular weight, testicular LH/hCG receptor levels or plasma testosterone. The potent LHRH agonist (D-Ala6, des-Gly-NH210) LHRH ethylamide at 500 ng s.c. for 2-4 weeks suppressed the testicular weight, testicular LH/hCG receptor levels, plasma testosterone levels, and caused atrophy of the androgen-dependent seminal vesicles and ventral prostate. The combination 4 week-treatment of medrogestone and LHRH agonist led to the most significant decrease of prostatic weight. The potential usefulness of this combination therapy in hormone-dependent cancers is discussed.
D000818:Animals; D001284:Atrophy; D004359:Drug Therapy, Combination; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D008297:Male; D008524:Medrogestone / Q000494:pharmacology*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D009929:Organ Size / Q000187:drug effects; D011245:Pregnadienes / Q000494:pharmacology*; D011467:Prostate / Q000473:pathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012669:Seminal Vesicles / Q000473:pathology; D013737:Testis / Q000473:pathology*; D013739:Testosterone / Q000097:blood
D006728:Hormones; D011245:Pregnadienes; D008524:Medrogestone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; C010661:surfagon